Alltrna has raised another $109 million in a series B to fund the Flagship Pioneering biotech's mission to "stop codon disease" with potential benefits for a range of genetic diseases caused by ...
For disorders driven by a known genetic component, research understandably focuses on developing a drug targeting that genetic signature. When that works, the outcome benefits patients but the end ...
Chronic Physical Effects and Health Care Utilization in Long-Term Ovarian Germ Cell Tumor Survivors: A Gynecologic Oncology Group Study ...
Genes hold the recipe for proteins, which are made of amino acids. DNA only has four letters, or nucleotides, and each sequence of three nucleotide bases, or codon, encodes for one amino acid. There ...
Codon-specific KRAS mutations are predictive of an overall survival (OS) benefit for metastatic colorectal cancer (mCRC) patients treated with trifluridine-tipiracil (FTD/TPI; Lonsurf), according to a ...
RAS co-mutation and early onset disease represent an aggressive phenotype of atypical (non-V600) BRAF mutant metastatic colorectal cancer. Biweekly mXELIRI versus FOLFIRI in combination with ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback